Ecothiopate iodide

Drug Profile

Ecothiopate iodide

Alternative Names: Echothiophate iodide; Ecostigmine iodide; Ecothiopate; Ecothiophate iodide; MI-100

Latest Information Update: 05 May 2015

Price : $50

At a glance

  • Originator Unknown
  • Developer Makindus
  • Class Antiglaucomas; Organothiophosphorus compounds
  • Mechanism of Action Acetylcholine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Stargardt disease

Most Recent Events

  • 04 May 2015 MI 100 receives Orphan Drug status for Stargardt disease 1 in European Union
  • 12 Jun 2014 Early research in Stargardt disease 1 (new dosage form) in USA (unspecified route)
  • 10 Jun 2014 MI 100 is available for licensing in USA as of 10 Jun 2014. www.makindus.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top